Jade Biosciences, Inc. (JBIO) stock
JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.40+0.06 (+0.42%)
Close on Nov 17, 2026Market cap $979.40MP/E –Yield –
Jade Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Jade Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $145.48M, up 120.1% year over year. For fiscal 2025 it was $93.12M, up 75.1% from the year before. The highest annual figure on record is $93.12M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.12M | +75.1% |
| FY2024 | Dec 31, 2024 | $53.19M | -17.2% |
| FY2023 | Dec 31, 2023 | $64.22M | +66.3% |
| FY2022 | Dec 31, 2022 | $38.62M | +157.7% |
| FY2021 | Dec 31, 2021 | $14.99M | +88.8% |
| FY2020 | Dec 31, 2020 | $7.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $30.82M | +40.0% |
| Q2 FY2026 | Jun 30, 2026 | $50.07M | +122.0% |
| Q1 FY2026 | Mar 31, 2026 | $36.05M | +80.1% |
| Q4 FY2025 | Dec 31, 2025 | $28.54M | +1764.2% |
| Q3 FY2025 | Sep 30, 2025 | $22.01M | +62.1% |
| Q2 FY2025 | Jun 30, 2025 | $22.55M | +6.1% |
| Q1 FY2025 | Mar 31, 2025 | $20.02M | -0.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.53M | -91.4% |
| Q3 FY2024 | Sep 30, 2024 | $13.58M | -19.6% |
| Q2 FY2024 | Jun 30, 2024 | $21.25M | +32.5% |
| Q1 FY2024 | Mar 31, 2024 | $20.08M | +48.9% |
| Q4 FY2023 | Dec 31, 2023 | $17.81M | +45.8% |
| Q3 FY2023 | Sep 30, 2023 | $16.88M | +56.6% |
| Q2 FY2023 | Jun 30, 2023 | $16.03M | +91.7% |
| Q1 FY2023 | Mar 31, 2023 | $13.49M | +85.9% |
| Q4 FY2022 | Dec 31, 2022 | $12.22M | +142.2% |
| Q3 FY2022 | Sep 30, 2022 | $10.78M | +215.5% |
| Q2 FY2022 | Jun 30, 2022 | $8.36M | +93.3% |
| Q1 FY2022 | Mar 31, 2022 | $7.26M | +230.4% |
| Q4 FY2021 | Dec 31, 2021 | $5.05M | +53.0% |
| Q3 FY2021 | Sep 30, 2021 | $3.42M | +73.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.33M | +194.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.97M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.47M | – |
See a number that looks wrong?